CANDEL THERAPEUTICS CADL 深 沪
已收盘 12-12 16:00:00 美东时间
6.35
-0.120
-1.85%
华盛通- 最 高6.55
- 今 开6.474
- 成交量 141.46万股
- 最 低 6.16
- 昨 收 6.47
- 总市值 3.49亿
- 52周最高 13.68
- 市盈率 静 --
- 换手率 2.58%
- 52周最低 4.25
- 委 比 3.91%
- 总股本 5489.51万
- 历史最高 14.78
- 量 比 0.97
- 振 幅 6.03%
- 历史最低 0.66
- 每 手 1
- 风险率 1.51%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
12-09 10:32
Stephens & Co. Reiterates Overweight on Candel Therapeutics, Maintains $15 Price Target
Stephens & Co. analyst Sudan Loganathan reiterates Candel Therapeutics (NASDAQ:CADL) with a Overweight and maintains $15 price target.
12-08 22:03
Candel Therapeutics To Present Data About Solid Tumors At Society For Immunotherapy Of Cancer In Maryland
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company developing multimodal biological immunotherapies to help patients fight cancer, today announced it will deliver
11-04 22:03
美股大行评级 | 上调！苹果、亚马逊、Amkor Tech、Cadence、Confluent、卡特、通用动力等获多家上调目标价
今日重点评级关注：HC Wainwright & Co.：维持PepGen"买入"评级，目标价从12美元升至18美元；Piper Sandler：维持Prothena Corp"超配"评级，目标价从15美元升至36美元
10-29 09:25
EXCLUSIVE: Trinity Capital's New Loan Fuels Bobbie's Mission To Set New US Infant Nutrition Standards
Trinity Capital Inc. announced a financing agreement with Bobbie, an organic infant nutrition company, to boost production capacity and ensure wider distribution of its products.
10-23 19:31
美股大行评级 | 富国银行上调苹果目标价升至290美元；"卖出"！花旗下调NuScale Power、阿特斯太阳能评级
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从30美元升至44美元；Piper Sandler：维持Vital Energy"中性"评级，目标价从16美元升至30美元
10-22 10:10
Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board
Candel Therapeutics appoints Bali Pulendran, Ph.D., a leading expert in systems immunology, to its Research Advisory Board. His加入 will support the advancement of Candel's viral immunotherapy candidates, CAN-2409 and CAN-3110, targeting solid tumors and recurrent high-grade glioma, respectively. With a proven track record in human immunology, Pulendran's expertise will enhance the development of innovative therapies to combat cancer across multipl...
10-16 12:05
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Strata Skin Sciences (NASDAQ:SSKN) shares increased by 44.9% to $2.23 ...
10-15 01:06
Candel Therapeutics Secures $130M Loan Facility To Fund Phase 3 Trial And Advance Cancer Pipeline
$50 million drawn down at closing, with access to up to an additional $80 millionStrengthens Company's financial position; enables initiation of phase 3 clinical trial of CAN-2409 in non-small cell lung cancer
10-14 20:14
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.
Candel Therapeutics announced a $130 million term loan facility with Trinity Capital to strengthen its financial position and support the phase 3 clinical trial of CAN-2409 in non-small cell lung cancer (NSCLC). The first tranche of $50 million has been drawn, with up to $80 million additional available. Proceeds will also prepare for a potential commercial launch in early localized prostate cancer. Candel highlights disciplined capital allocatio...
10-14 12:10
